BACKGROUND: The current study was conducted to report the severity and management of canalicular and @entity850 as a side effect of @entity1205 therapy and to report the outcomes of surgical intervention for this condition. METHODS: The records of 148 @entity1 with @entity9467 associated with @entity1205 therapy who were evaluated at the Ophthalmology Service at The University of Texas M. D. Anderson @entity5 Center were reviewed. The frequency of @entity1205 administration, the dose intensity, the cumulative dose of @entity1205 , and any concomitant chemotherapeutic agents were recorded. Each @entity1 underwent an ophthalmologic examination and in-office probing and irrigation. The @entity1 either were treated with topical @entity230 or offered a surgical procedure for canalicular @entity850 - ( @entity1346 intubation, dacryocystorhinostomy [DCR] with the placement of @entity1346 tubes, or DCR with the placement of Pyrex glass tubes), depending on the severity of the canalicular @entity850 . RESULTS: @entity1205 was given weekly in 71 @entity1 , every 2 weeks in 5 @entity1 , and every 3 weeks in 72 @entity1 . Thirty @entity1 (59 eyes) who received weekly @entity1205 underwent surgery to correct @entity9467 . Twenty-three @entity1 (39 eyes) were treated with temporary @entity1346 tube placement, 9 @entity1 (13 eyes) were treated with DCR with temporary @entity1346 tube placement, and 4 @entity1 (7 eyes) were treated with DCR with permanent Pyrex glass tube placement. Twenty-nine of the 30 @entity1 who underwent surgery reported improvement or total resolution of @entity9467 after the procedure. Ten additional @entity1 (20 eyes) who received weekly @entity1205 had complete closure of their canaliculi but elected not to undergo surgery. Of special note were two @entity1 who received weekly @entity1205 in the neoadjuvant setting and developed complete closure of the canaliculi. Of the @entity1 who received @entity1205 every 2 or 3 weeks, only 3 required a surgical intervention to correct @entity9467 ; none required Pyrex glass tube placement. CONCLUSIONS: Canalicular and nasolacrimal duct obstruction is a common side effect of weekly @entity1205 therapy and can occur even when this drug is used in the neoadjuvant setting. The results of the current study indicate that early temporary @entity1346 intubation in symptomatic @entity1 receiving weekly @entity1205 can prevent further closure of the lacrimal drainage apparatus and obviate more involved surgical interventions and permanent Pyrex glass tube placement. @entity5 2003;98:504-7.

Blockage of the lacrimal drainage apparatus as a side effect of XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity9467 :: ('MESH:D007766', 'Disease') :: ['epiphora'] @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity850 :: ('MESH:D003251', 'Disease') :: ['nasolacrimal duct stenosis', 'stenosis'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel', 'Docetaxel']
@entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']
